Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Input: Consider Input: Increased expression of nerve growth factor in injured or inflamed tissue is associated with increased pain. This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor. We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 g per kilogram of body weight) or placebo on days 1 and 56. The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy. We also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety. When averaged over weeks 1 through 16, the mean reductions from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). Tanezumab, as compared with placebo, was also associated with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P0.001). The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P<0.001). The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, respectively. The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%). In this proof-of-concept study, treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee. (Funded by Rinat Neuroscience; ClinicalTrials.gov number, NCT00394563.).

Output: What is the target of tanezumab?


Input: Consider Input: Plunkett finished the game with 16 out of 25 pass completions for 172 yards and a touchdown. Theismann threw for more yards than Plunkett (243), but was just 16 out of 35 and was intercepted twice. He was also sacked six times. Branch was the top receiver of the game with six receptions for 94 yards and a touchdown. Guy punted seven times for 299 yards (42.7 average), with 244 net yards (34.8 average) and planted five of his seven punts inside the 20. Martin recorded a sack, a pass deflection, and a fumble recovery. Riggins, who had rushed for over 100 yards in his last six postseason games, was held to 64 yards and a touchdown on 26 carries, with his longest gain being just 8 yards. Brown was their top receiver with three receptions for 93 yards. Tight end Clint Didier caught five passes for 65 yards. Garrett recorded 100 yards on kickoff returns, and one reception for 17 yards. Part of both of Allens touchdown runs were cutbacks, which, according to New York Daily News writer Larry Fox, burned an overpursuing Redskins defense.

Output: Which player achieved more receptions, Branch or Brown?


Input: Consider Input: Extrapolating the figures from a previous study on FSHD in a province of The Netherlands to the entire Dutch population suggests that at present a nearly complete overview is obtained of all symptomatic kindred. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. A mutation frequency of 9.6% was calculated. Mental retardation and severe retinal vasculopathy were reported in low frequencies (1%). Early onset was seen more frequently in sporadic cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal-dominant families. The clinical pictures in the linked and nonlinked families were identical.


Output: What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?